Andere talen Syndax Pharmaceuticals, Inc.

Aandelen

SNDX

US87164F1057

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
21,06 ^USD	+2,38%		+1,25%	-2,55%

08/04	Syndax Pharmaceuticals, Inc. Presenteert positieve pediatrische gegevens van de Pivotal AUGMENT-101 studie met Revumenib in recidiverende/refractaire acute leukemie van KMT2Ar tijdens de ASPHO Plenary Session	CI
28/03	Syndax Pharmaceuticals, Inc. Kondigt de voltooiing aan van de inclusie in het AUGMENT-101 pivotaal studiecohort van patiënten met recidief/refractaire mNPM1 acute myeloïde leukemie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum	10/04
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	09/04
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	08/04
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05/04
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	28/03
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed, Refractory KMT2Ar Acute Leukemia	27/03
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment	26/03
Syndax Says Revumenib NDA Granted FDA Priority Review	26/03
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia	26/03
Sector Update: Health Care Stocks Rise Monday Afternoon	18/03
Syndax Pharmaceuticals Names Steven Closter Chief Commercial Officer	18/03
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer	18/03
Syndax Pharmaceuticals, Inc. Announces Executive Changes	18/03
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	01/03
Syndax: Q4 Earnings Snapshot	27/02
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Syndax Announces Participation at Two Upcoming Investor Conferences	26/02
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024	20/02
Certain Restricted Stock Units of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024.	13/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Syndax Pharmaceuticals, Inc.

Aandelen

SNDX

US87164F1057

Andere talen

Filters